Kairos Pharma Files 8-K; CEO to Present Investor Presentation at H.C. Wainwright

What Happened

• On September 14, 2026, Kairos Pharma, Ltd. filed an 8-K (Item 7.01) to disclose a new investor presentation that will be posted on the company website and presented at the H.C. Wainwright 28th Annual Global Investment Conference in New York (Sept 14–16, 2026). CEO John Yu will present the slide deck to provide an update on the company’s clinical program and activities. The presentation has been furnished as Exhibit 99.1 to the filing.

Key Details

• Filing date: September 14, 2026 (Form 8-K, Regulation FD disclosure, Item 7.01).
• Event: H.C. Wainwright 28th Annual Global Investment Conference, New York, Sept 14–16, 2026.
• Presenter: John Yu, Chief Executive Officer.
• Materials: Investor presentation will be published on www.kairospharma.com and is furnished as Exhibit 99.1 to the 8-K.

Why It Matters

• The filing informs investors of a public update from management on Kairos’s clinical program and activities; the presentation will be available on the company website.
• This is a Regulation FD disclosure (non-financial) — it does not report earnings, executive changes, or deal terms, but signals a scheduled investor update that may contain clinical or program progress worth reviewing.